Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells
This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.
Patent Number
US 10307490
Status
Active
Filing Date
May 23, 2013
Grant Date
June 4, 2019
Expiration
May 23, 2033
Claims
35
Assignee
The Ohio State University
Inventors
Young Bok Lee, Chang Ho Ahn, Deog Joong Kim, Robert J. Lee
Citations
3 forward · 27 backward
What it covers
This patent describes a special type of tiny package called a lipid-coated albumin nanoparticle (LCAN) designed to deliver therapeutic agents. The LCAN is built around a core that is positively charged and contains an albumin-polycation conjugate, as specified in claim 1. This core can encapsulate a therapeutic agent, such as an antisense oligonucleotide (ASO) that targets genes like Akt-1 or HIF-1, as detailed in claims 2 and 3. The entire core is then wrapped in a positively-charged lipid layer, called a cationic liposome. Crucially, the nanoparticle also includes a 'targeting agent' (claim 1), which acts like a homing beacon to guide the package to specific cells or tissues, using molecules like RGD peptides or folate (claim 8). For example, this system could deliver an ASO to cancer cells, blocking a gene that helps them grow, while minimizing effects on healthy cells.
What it doesn't cover
- —Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.
- —Does not cover nanoparticles where the core is not net positively-charged or does not contain an albumin-polycation conjugate.
- —Does not cover delivery systems that lack a specific targeting agent to direct the nanoparticle to certain cells.
- —Does not cover lipid nanoparticles that are purely anionic or neutral in charge, as the claims specify a 'cationic liposome' and a 'net positively-charged core'.
- —Does not cover delivery of therapeutic agents that are not encapsulated within the core of the nanoparticle.
The clever bit
The clever part is combining a stable, positively-charged protein-polycation core with a cationic lipid shell and a specific targeting agent. This creates a robust, targeted nanoparticle that can effectively encapsulate and deliver negatively-charged therapeutic agents like ASOs, ensuring they reach their intended cellular destination.
Why it matters
This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.
Real-world examples
- 1.Targeted cancer therapies using nanoparticles
- 2.Gene therapy delivery systems
- 3.Antisense oligonucleotide (ASO) drug formulations
- 4.mRNA vaccine delivery (using lipid nanoparticles)
- 5.Drug delivery systems for inflammatory diseases
Generated by PatentBrief · Not legal advice · patentbrief.org
US 10307490 · 2026